{"filing":{"accession_number":"0001178913-26-004823","cik":"0001498403","ticker":"BLRX","company_name":"BioLineRx Ltd.","form":"6-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"zk2636256.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1498403/000117891326004823/zk2636256.htm"},"events":[{"id":37423,"run_id":34495,"accession_number":"0001178913-26-004823","anchor_item_number":"EX-99","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces preclinical data presented at ESMO 2026 demonstrating synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, with plans to add an ovarian cancer arm to the ongoing Phase 1/2a clinical trial. The disclosure is a material operational/strategic milestone—positive preclinical results supporting expansion of a lead program into a new indication—but does not fit the discrete event categories (no M\u0026A, no exec change, no financial obligation, no litigation). The data presentation and planned trial expansion represent a significant development in the company's therapeutic pipeline and clinical strategy.","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-10-23","form":"6-K","submitted_at":null,"items":[{"id":42130,"accession_number":"0001178913-26-004823","item_number":"EX-99","item_title":"exhibit_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces preclinical data presented at ESMO 2026 demonstrating synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, with plans to add an ovarian cancer arm to the ongoing Phase 1/2a clinical trial. The disclosure is a material operational/strategic milestone—positive preclinical results supporting expansion of a lead program into a new indication—but does not fit the discrete event categories (no M\u0026A, no exec change, no financial obligation, no litigation). The data presentation and planned trial expansion represent a significant development in the company's therapeutic pipeline and clinical strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T11:06:38.015900+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42130,"accession_number":"0001178913-26-004823","item_number":"EX-99","item_title":"exhibit_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces preclinical data presented at ESMO 2026 demonstrating synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, with plans to add an ovarian cancer arm to the ongoing Phase 1/2a clinical trial. The disclosure is a material operational/strategic milestone—positive preclinical results supporting expansion of a lead program into a new indication—but does not fit the discrete event categories (no M\u0026A, no exec change, no financial obligation, no litigation). The data presentation and planned trial expansion represent a significant development in the company's therapeutic pipeline and clinical strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T11:06:38.015900+00:00","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-10-23"}]}